Title	Publication Date	Language	Citations
Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation	2003/01/01		275
Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML	2003/01/01		160
The effect of iron deficiency anemia on the function of the immune system	2005/01/01		150
Mesenchymal stem cell: use and perspectives	2003/01/01		122
Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma	2004/01/01		103
Female donors influence transplant-related mortality and relapse incidence in male recipients of sibling blood and marrow transplants	2001/01/01		94
Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma	2004/01/01		93
Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma	2004/01/01		92
Gp130 and ras mediated signaling in human plasma cell line INA-6: a cytokine-regulated tumor model for plasmacytoma	2001/01/01		86
XIAP expression correlates with monocytic differentiation in adult de novo AML: impact on prognosis	2004/01/01		78
A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia/lymphoma	2002/01/01		77
Overwhelming postsplenectomy infection: is quality of patient knowledge enough for prevention?	2004/01/01		75
High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib	2004/01/01		72
Tumor necrosis factor α release is a major biological event associated with rituximab treatment	2001/01/01		72
Role of coagulation testing in predicting bleeding risk	2003/01/01		62
A prospective comparison of fine-needle aspiration cytology and histopathology in the diagnosis and classification of lymphomas	2004/01/01		55
A clinical, molecular and cytogenetic study of 12 cases of human herpesvirus 8 associated primary effusion lymphoma in HIV-infected patients	2001/01/01		54
Variability in B-cell antigen expression: implications for the treatment of B-cell lymphomas and leukemias with monoclonal antibodies	2001/01/01		53
Variable prognostic value of FLT3 internal tandem duplications in patients with de novo AML and a normal karyotype, t(15;17), t(8;21) or inv(16)	2002/01/01		51
Prognostic significance of FLT3 ITD and D835 mutations in AML patients	2003/01/01		49
Bacteraemia in hospitalised patients with malignant blood disorders: a retrospective study of causative agents and their resistance profiles during a 14-year period without antibacterial prophylaxis	2003/01/01		46
Antiphospholipid antibodies in lymphoma: prevalence and clinical significance	2004/01/01		45
Myelodysplastic syndromes	2004/01/01		44
Fertility in young women after chemotherapy with alkylating agents for Hodgkin and non-Hodgkin lymphomas	2003/01/01		43
Disseminated intravascular coagulation	2003/01/01		42
Nuclear transplantation, embryonic stem cells and the potential for cell therapy	2004/01/01		42
CD38 expression as a prognostic indicator in chronic lymphocytic leukaemia	2004/01/01		40
Myeloablative radiochemotherapy followed by autologous peripheral blood stem cell transplantation as first-line therapy in peripheral T-cell lymphomas: first results of a prospective multicenter study	2004/01/01		39
Clinical variability of patients with the t(6;8)(q27;p12) and FGFR1OP-FGFR1 fusion: two further cases	2004/01/01		37
Characterisation of TP53 abnormalities in chronic lymphocytic leukaemia	2004/01/01		36